Activity
Amylyx Reveals Interim Rare Disease Data for Withdrawn ALS Therapy
Amylyx, Rare disease data, ALS drug withdrawal, Interim results, Rare neurological disorder
Vertex Acquires Alpine Immune Sciences for $4.9 Billion to Boost Immunology Trail
Vertex Pharmaceuticals, Alpine Immune Sciences, $4.9 billion acquisition, Immunology trail
Enhanced Optimization for Influenza B Strains Planned in CureVac’s mRNA Seasonal Flu Vaccine Trials
CureVac, mRNA flu vaccine, Influenza B strains, Targeted optimization, Phase 2 studies, Multivalent candidate, Improved immune response, Collaboration with GSK
Sanofi Settles 4,000 Zantac Cancer Lawsuits, Faces Delaware Claims
Sanofi, Zantac, Cancer Lawsuits, Settlement, Delaware Claims, 4/000 Lawsuits, Delaware Superior Court, Daubert Ruling
Experts Commend Amylyx for Withdrawing ALS Drug Relyvrio Following Trial Failure
Amylyx, Relyvrio, ALS drug, Trial failure, Market withdrawal, Promise kept
Merck KGaA Partners with AI Techbio Caris Discovery for ADC Discovery, Up to $1.4 Billion in Milestones
Merck KGaA, AI techbio, Caris Discovery, Antibody-Drug Conjugates (ADC), $1.4 billion milestones, ADC discovery deal
Genmab Acquires ProfoundBio for $1.8 Billion to Challenge AbbVie’s Elahere in ADC Market
Genmab, ProfoundBio, $1.8 billion acquisition, Antibody Drug Conjugates (ADCs), Competition with AbbVie’s Elahere, Rinatabart sesutecan (Rina-S), Folate Receptor Alpha (FRα), Midphase clinical trials
Carisma Therapeutics to Lay Off Staff, Discontinue CAR-M Programs in Pursuit of Second Candidate
Carisma Therapeutics, Layoffs, Workforce reduction (37%), Dropping clinical CAR-M program, Anti-HER2 CAR-macrophage CT-0508, Anti-mesothelin CAR-monocyte candidate CT-1119, Second candidate focus
AstraZeneca’s Ultomiris Gains FDA Approval for Rare Autoimmune Condition – NMOSD
AstraZeneca, Ultomiris, ravulizumab-cwvz, FDA Approval, Rare Autoimmune Disease, Neuromyelitis Optica Spectrum Disorder (NMOSD), Long-acting C5 complement inhibitor, Phase 3 CHAMPION-NMOSD Trial, Reduced Relapse Rate, Dosing Frequency
Novo Nordisk Acquires Mid-Stage Heart Failure Biotech Cardior for Up to $1.1 Billion
Novo Nordisk, Cardior Pharmaceuticals, Heart Failure Biotech, Acquisition, $1.1 billion